サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1728331

シンバスタチン市場- 世界の産業規模、シェア、動向、機会、予測、販売チャネル別、最終用途別、地域別、競合別セグメント、2020-2030年

Simvastatin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel, By End Use, By Region and Competition, 2020-2030F

出版日
ページ情報
英文 185 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.28円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

シンバスタチン市場- 世界の産業規模、シェア、動向、機会、予測、販売チャネル別、最終用途別、地域別、競合別セグメント、2020-2030年
出版日: 2025年05月16日
発行: TechSci Research
ページ情報: 英文 185 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

シンバスタチンの世界市場は、2024年に1億4,693万米ドルと評価され、予測期間中にCAGR 6.51%で成長し、2030年には2億2,687万米ドルに達すると予測されています。

シンバスタチンは、スタチンクラスに属するコレステロール低下薬で、高コレステロール血症の管理と心血管合併症の予防に広く使用されています。予防医療とコレステロール管理に対する社会的関心の高まりが、成熟市場と新興市場の両方で需要を促進しています。この市場は、肥満、糖尿病、高血圧などのライフスタイルに関連した疾患の有病率の上昇から利益を得ており、これらの疾患は心血管リスクを高め、早期のスタチン治療を促しています。シンバスタチンは、利用可能な治療法のなかでも確立された費用対効果の高い選択肢です。低所得国では、ヘルスケアサービスへのアクセスが拡大し、ジェネリック医薬品の価格も手頃になったことが、市場の拡大を支えています。しかし、業界は代替脂質低下療法との競合、スタチンの長期使用に関する安全性に関する懸念、メーカーの価格設定や利益率に影響を与える規制上の制約などとも戦っています。

市場概要
予測期間 2026-2030
市場規模：2024年 1億4,693万米ドル
市場規模：2030年 2億2,687万米ドル
CAGR：2025年～2030年 6.51%
急成長セグメント ダイレクト
最大市場 アジア太平洋

市場促進要因

製薬業界の成長

主な市場課題

安全性への懸念と副作用

主要市場動向

政府のヘルスケア支出の増加

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界のシンバスタチン市場に与える影響

第5章 世界のシンバスタチン市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 販売チャネル別（直接、間接）
    • 用途別（高脂血症、冠動脈性心疾患、糖尿病性脂質異常症、脳卒中、その他）
    • 地域別
    • 企業別（2024）
  • 市場マップ

第6章 北米のシンバスタチン市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • メキシコ
    • カナダ

第7章 欧州のシンバスタチン市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第8章 アジア太平洋地域のシンバスタチン市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋地域：国別分析
    • 中国
    • インド
    • 韓国
    • 日本
    • オーストラリア

第9章 南米のシンバスタチン市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカのシンバスタチン市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 合併と買収
  • 製品上市
  • 最近の動向

第13章 世界のシンバスタチン市場：SWOT分析

第14章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第15章 競合情勢

  • ASolution Pharmaceuticals Pvt. Ltd
  • Cipla Ltd
  • Cadila Healthcare Limited
  • Jsons Laboratories
  • SHIVA LIFE SCIENCE PVT LTD
  • Kaizen Pharmachem
  • Rajem Pharmascience Pvt Ltd
  • Jubilant Generics Limited
  • Chemneal Pharmaceuticals LLP
  • Sun Pharmaceutical Industries Limited

第16章 戦略的提言

第17章 調査会社について・免責事項

目次
Product Code: 29085

The Global Simvastatin Market was valued at USD 146.93 million in 2024 and is projected to reach USD 226.87 million by 2030, growing at a CAGR of 6.51% during the forecast period. Simvastatin, a cholesterol-lowering drug in the statin class, is extensively used for managing hypercholesterolemia and preventing cardiovascular complications. Increasing public focus on preventive healthcare and cholesterol control is fueling its demand across both mature and emerging markets. The market benefits from the rising prevalence of lifestyle-related disorders such as obesity, diabetes, and hypertension-conditions that heighten cardiovascular risks and prompt early statin therapy. Simvastatin remains a well-established and cost-effective option among available treatments. Broader access to healthcare services and greater affordability of generic drugs in lower-income nations are supporting market expansion. However, the industry also contends with competition from alternative lipid-lowering therapies, safety-related concerns regarding long-term statin use, and regulatory constraints that may impact pricing and profit margins for manufacturers.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 146.93 Million
Market Size 2030USD 226.87 Million
CAGR 2025-20306.51%
Fastest Growing SegmentDirect
Largest MarketAsia Pacific

Key Market Drivers

Growth in Pharmaceutical Industry

The expansion of the global pharmaceutical industry is a major driver propelling simvastatin demand. With the pharmaceutical sector generating over USD 1.6 trillion in revenue by 2023, its scale is now comparable to the GDP of entire nations. This growth reflects a heightened industry focus on chronic disease management, including cardiovascular conditions-a key area where statins like simvastatin play a central role. As companies increase investments in accessible, cost-effective therapies, the use of generic statins continues to rise globally. Simvastatin, due to its proven efficacy and affordability, remains a staple treatment, particularly in managing long-term cardiovascular risk in both primary and secondary prevention cases.

Key Market Challenges

Safety Concerns and Side Effects

Safety concerns related to simvastatin pose a significant challenge to its continued uptake. Although effective in managing cholesterol levels and lowering cardiovascular risk, simvastatin has been associated with muscle-related side effects, ranging from mild discomfort to serious conditions such as myopathy and rhabdomyolysis. These risks, especially with prolonged use or when combined with interacting drugs like antifungals or immunosuppressants, have led to increased caution among healthcare providers and patients. Regulatory bodies continue to evaluate the risk-benefit profile of simvastatin, and some patients may avoid or discontinue therapy due to perceived or actual adverse effects. These safety issues can impact treatment adherence and overall market performance.

Key Market Trends

Increasing Government Healthcare Spending

Rising government expenditure on healthcare is a key trend supporting simvastatin market growth. In 2023, the U.S. reported healthcare spending of USD 13,432 per capita-well above the average of USD 7,393 among other high-income countries. Similar trends are emerging globally as nations prioritize public health infrastructure and chronic disease prevention. Simvastatin, frequently included on essential medicine lists, benefits from government-led programs that subsidize or reimburse treatments for hyperlipidemia and cardiovascular disease. By supporting early intervention and preventative care through expanded access to medicines, increased public spending plays a crucial role in boosting simvastatin usage, particularly in regions implementing large-scale cardiovascular disease mitigation strategies.

Key Market Players

  • ASolution Pharmaceuticals Pvt. Ltd
  • Cipla Ltd
  • Cadila Healthcare Limited
  • Jsons Laboratories
  • SHIVA LIFE SCIENCE PVT LTD
  • Kaizen Pharmachem
  • Rajem Pharmascience Pvt Ltd
  • Jubilant Generics Limited
  • Chemneal Pharmaceuticals LLP
  • Sun Pharmaceutical Industries Limited

Report Scope:

In this report, the Global Simvastatin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Simvastatin Market, By Sales Channel:

  • Direct
  • Indirect

Simvastatin Market, By End Use:

  • Hyperlipidemia
  • Coronary Heart Disease
  • Diabetes-Related Dyslipidemia
  • Stroke
  • Others

Simvastatin Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Simvastatin Market.

Available Customizations:

Global Simvastatin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Simvastatin Market

5. Global Simvastatin Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Sales Channel (Direct, Indirect)
    • 5.2.2. By End Use (Hyperlipidemia, Coronary Heart Disease, Diabetes-Related Dyslipidemia, Stroke, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Simvastatin Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Sales Channel
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Simvastatin Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Sales Channel
        • 6.3.1.2.2. By End Use
    • 6.3.2. Mexico Simvastatin Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Sales Channel
        • 6.3.2.2.2. By End Use
    • 6.3.3. Canada Simvastatin Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Sales Channel
        • 6.3.3.2.2. By End Use

7. Europe Simvastatin Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Sales Channel
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Simvastatin Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Sales Channel
        • 7.3.1.2.2. By End Use
    • 7.3.2. Germany Simvastatin Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Sales Channel
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom Simvastatin Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Sales Channel
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Simvastatin Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Sales Channel
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Simvastatin Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Sales Channel
        • 7.3.5.2.2. By End Use

8. Asia Pacific Simvastatin Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Sales Channel
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Simvastatin Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Sales Channel
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Simvastatin Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Sales Channel
        • 8.3.2.2.2. By End Use
    • 8.3.3. South Korea Simvastatin Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Sales Channel
        • 8.3.3.2.2. By End Use
    • 8.3.4. Japan Simvastatin Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Sales Channel
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Simvastatin Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Sales Channel
        • 8.3.5.2.2. By End Use

9. South America Simvastatin Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Sales Channel
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Simvastatin Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Sales Channel
        • 9.3.1.2.2. By End Use
    • 9.3.2. Argentina Simvastatin Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Sales Channel
        • 9.3.2.2.2. By End Use
    • 9.3.3. Colombia Simvastatin Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Sales Channel
        • 9.3.3.2.2. By End Use

10. Middle East and Africa Simvastatin Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Sales Channel
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Simvastatin Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Sales Channel
        • 10.3.1.2.2. By End Use
    • 10.3.2. Saudi Arabia Simvastatin Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Sales Channel
        • 10.3.2.2.2. By End Use
    • 10.3.3. UAE Simvastatin Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Sales Channel
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Simvastatin Market: SWOT Analysis

14. Porters Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. ASolution Pharmaceuticals Pvt. Ltd
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Cipla Ltd
  • 15.3. Cadila Healthcare Limited
  • 15.4. Jsons Laboratories
  • 15.5. SHIVA LIFE SCIENCE PVT LTD
  • 15.6. Kaizen Pharmachem
  • 15.7. Rajem Pharmascience Pvt Ltd
  • 15.8. Jubilant Generics Limited
  • 15.9. Chemneal Pharmaceuticals LLP
  • 15.10. Sun Pharmaceutical Industries Limited

16. Strategic Recommendations

17. About Us & Disclaimer